iifl-logo-icon 1

Polar Pharma India Ltd Share Price

0.82
(-4.65%)
Sep 17, 2013|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Polar Pharma India Ltd KEY RATIOS

Sector

Miscellaneous

Open

0.82

Prev. Close

0.86

Turnover(Lac.)

0

Day's High

0.82

Day's Low

0.82

52 Week's High

0

52 Week's Low

0

Book Value

-103.63

Face Value

10

Mkt Cap (₹ Cr.)

1.01

P/E

0

EPS

0

Divi. Yield

0

Polar Pharma India Ltd Corporate Action

No Record Found

Polar Pharma India Ltd NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Polar Pharma India Ltd SHAREHOLDING SNAPSHOT

10 Feb, 2025|06:13 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 29.74%

Foreign: 0.00%

Indian: 29.74%

Non-Promoter- 2.64%

Institutions: 2.63%

Non-Institutions: 67.61%

Custodian: 0.00%

Share Price

Polar Pharma India Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2012Mar-2011Mar-2010Mar-2009

Equity Capital

12.27

12.27

12.27

12.27

Preference Capital

1.25

1.25

1.25

1.25

Reserves

-127.74

-108.84

-95.31

-79.22

Net Worth

-114.22

-95.32

-81.79

-65.7

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2012Mar-2011

Revenue

16.2

10.91

yoy growth (%)

48.48

Raw materials

-8.38

-3.51

As % of sales

51.73

32.23

Employee costs

-3.75

-1.68

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2012Mar-2011

Profit before tax

-18.91

-13.49

Depreciation

-2.25

-2.23

Tax paid

0

0

Working capital

-1.16

Other operating items

View Cash Flow
Y/e 31 MarMar-2012Mar-2011

Growth matrix (%)

Revenue growth

48.48

Op profit growth

-199.65

EBIT growth

2,417.34

Net profit growth

39.66

View Ratios
Particulars (Rupees in Crores.)Mar-2009Mar-2008Mar-2007

Gross Sales

0.25

25.85

18.87

Excise Duty

0

0

0

Net Sales

0.25

25.85

18.87

Other Operating Income

0

0

0

Other Income

1.16

0.18

1.75

Polar Pharma India Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

GMR Airports Ltd

GMRAIRPORT

74.54

078,706.61-49.430270.9245.21

Sagility India Ltd

SAGILITY

52.77

119.9324,703.37110.110453.721.3

OneSource Specialty Pharma Ltd

ONESOURCE

1,525.95

017,462.36-73.020336.7536.2

Rites Ltd

RITES

232.2

30.2311,159.6294.993.88544.5351.59

Equinox India Developments Ltd

EMBDL

149.55

09,518.42-15.2604.8379.21

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Polar Pharma India Ltd

Management

Register Office

Registrar Office

Chairman & Managing Director

Anil Agarwal

Vice Chairman

Sunil Agarwal

Director

Madhu S Mishra

Director

Ved Prakash Jain

Director

Uma Shankar Sanganerie

Additional Director

Kishanlal Sharma

Company Secretary

Rupa Gupta

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Incorporated as a public limited company in Dec.88, Polar Pharma India Ltd., formerly known as Polar Latex was promoted in the joint sector by the Industrial Promotion and Investment Corporation of Orissa (IPICOL) along with the Polar group, in technical collaboration with Hindustan Latex (a Government of India undertaking). Hindustan Latex is the worlds largest manufacturer of condoms.The company manufactures rubber prophylactics. It has a plant at Balasore, Orissa. It came out with a public issue in Jun.90 to part-finance this project. The main raw material required by the company is latex, which is procured from Kerala and Tamilnadu. It markets its condoms under the Adam brand name.During 1993-94, the company undertook a diversification-cum-expansion programme to expand its plant capacity for latex prophylactics from 160 mln pa to 400 mln pa and to set up an unit (inst. cap. : 518 mln pa) to manufacture finger cots. The company exports its product to Switzerland, Canada, South Korea, Lithuania, Baltic Republics, Russia, the UK, Korea and the CIS countries. The company products are registered with the Food and Drug Adminstration (FDA) of USA, The South African Bureau of Standards (SABS), The Ministry of Health and Medical Industry of the Russian Federation, Department of Drug & Medical Equipment, Ministry of Health, Uzbekistan and the Federal Ministry of Health (FMH), Nigeria.During 1999-2000, the company received the grant of license for Private Bonded Warehouse under the
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.